ライフサイエンスコーパス: mycophenolate mofetil

1 eiving calcineurin inhibitors, steroids, and mycophenolate mofetil.

2 erious effects of rapamycin, tacrolimus, and mycophenolate mofetil.

3 estimated GFR, male sex, and treatment with mycophenolate mofetil.

4 imen consisting of tacrolimus, steroids, and mycophenolate mofetil.

5 revented by immunosuppression with FK506 and mycophenolate mofetil.

6 pression, all dogs received cyclosporine and mycophenolate mofetil.

7 ften in patients given cyclophosphamide than mycophenolate mofetil.

8 te globulin induction and were maintained on mycophenolate mofetil.

9 immunosuppression regimens of tacrolimus and mycophenolate mofetil.

10 graft recipients treated with tacrolimus and mycophenolate mofetil.

11 for 3 days and then stopped), tacrolimus and mycophenolate mofetil.

12 ive agent was cyclosporine or tacrolimus and mycophenolate mofetil.

13 lls and posttransplantation cyclosporine and mycophenolate mofetil.

14 withdrawal of calcineurin antagonists and/or mycophenolate mofetil.

15 There is an increased use of mycophenolate mofetil.

16 FK506 but can be blocked by the presence of mycophenolate mofetil.

17 rrow infusion then steroids, tacrolimus, and mycophenolate mofetil.

18 e immunosuppression (IS) with tacrolimus and mycophenolate mofetil.

19 d thymoglobulin, tacrolimus, prednisone, and mycophenolate mofetil.

20 ts were randomized to methotrexate and 39 to mycophenolate mofetil.

21 n between patients receiving methotrexate or mycophenolate mofetil.

22 ly for 2 days) and GVHD immunoprophylaxis of mycophenolate mofetil (1 g three times a day, days 0-28)

23 ive oral methotrexate, 25 mg weekly, or oral mycophenolate mofetil, 1 g twice daily, and were followe

24 Tacrolimus, 4 mg/d, and mycophenolate mofetil, 1.0 g/d, versus intravenous cyclo

25 dnisone, 40 mg/d, tapered over 6 months, and mycophenolate mofetil, 1000 mg twice daily, for a mean o

26 , total body irradiation, cyclosporine A and mycophenolate mofetil (12 doses), and antilymphocyte ser

27 itor-withdrawn, sirolimus 8 to 12 ng/mL with mycophenolate mofetil 2 g two times per day.

28 , double-dummy, phase 3 study comparing oral mycophenolate mofetil (2 g per day) and oral azathioprin

29 Post grafting immunosuppression consisted of mycophenolate mofetil (28 days) and cyclosporine (35 day

30 preva Lupus Management Study (ALMS) trial of mycophenolate mofetil, 3) the Lupus Nephritis Assessment

31 ts were randomized to methotrexate and 16 to mycophenolate mofetil; 30 had acute VKH.

32 vents was higher with azathioprine than with mycophenolate mofetil (39.6% vs. 25.2%, P = 0.02).

33 .3 mg/kg), with planned low-dose maintenance mycophenolate mofetil (500 mg twice daily) and tacrolimu

34 or tacrolimus and an antimetabolite, mostly mycophenolate mofetil (91.7%).

35 es (95% CI: 0.6, 9.8; P = .20) the odds with mycophenolate mofetil, a difference that was not statist

36 fidence interval [CI] 2.03-6.39), Neoral and mycophenolate mofetil (AHR 2.09, CI 1.31-3.31), and siro

37 (AHR 2.09, CI 1.31-3.31), and sirolimus and mycophenolate mofetil (AHR 2.77, CI 1.40-5.47), were ass

38 g enteric-coated mycophenolate sodium versus mycophenolate mofetil along with reduced maintenance tac

39 he mammalian target of rapamycin [mTOR]) and mycophenolate mofetil (an inosine monophosphate dehydrog

40 nolic acid (MPA) is the active metabolite of mycophenolate mofetil, an effective immunosuppressive dr

41 d prolonged-release tacrolimus, basiliximab, mycophenolate mofetil and 1 bolus of intraoperative cort

42 16 (11%) patients died (five [7%] mycophenolate mofetil and 11 [15%] cyclophosphamide), wi

43 ly assigned to maintenance treatment (116 to mycophenolate mofetil and 111 to azathioprine).

44 Postgrafting immunosuppression included mycophenolate mofetil and a calcineurin inhibitor.

45 tion of newer steroid-sparing agents such as mycophenolate mofetil and a new class of immunomodulator

46 aCD20 antibody, followed by maintenance with mycophenolate mofetil and an intensively dosed alphaCD40

47 Large controlled trials using mycophenolate mofetil and azathioprine for maintenance t

48 e that conventional immunomodulators such as mycophenolate mofetil and biologics such as rituximab ar

49 QD 0.3 mg/kg per day (Arm 3; n=304) all with mycophenolate mofetil and corticosteroids (tapered) over

50 regimens or placebo, both on a background of mycophenolate mofetil and corticosteroids.

51 the % FVC improved significantly in both the mycophenolate mofetil and cyclophosphamide groups.

52 GVHD prophylaxis was mycophenolate mofetil and cyclosporine.

53 her abatacept or placebo, on a background of mycophenolate mofetil and glucocorticoids.

54 All patients received cyclosporine and mycophenolate mofetil and gradually tapered prednisone.

55 nt and graft survivals after introduction of mycophenolate mofetil and induction with basiliximab.

56 was no clear difference in efficacy between mycophenolate mofetil and intravenous cyclophosphamide i

57 e active immunosuppressive substance in both mycophenolate mofetil and mycophenolate sodium, and it i

58 ll case series suggest that a combination of mycophenolate mofetil and prednisone may be an effective

59 On the background of negative trials with mycophenolate mofetil and rituximab, there are recent da

60 low and even no oral steroids can be used in mycophenolate mofetil and rituximab-based regimes.

61 ave unexpected ALPS-specific toxicities, and mycophenolate mofetil and sirolimus have been demonstrat

62 maintenance with tacrolimus with or without mycophenolate mofetil and steroids.

63 d with 30% to 50% reduction in doses of both mycophenolate mofetil and Tac without antiviral therapy.

64 on and SF immunosuppression with maintenance mycophenolate mofetil and tacrolimus between October 200

65 py with a T cell-depleting agent followed by mycophenolate mofetil and tacrolimus is presently the mo

66 Mean doses reduction of mycophenolate mofetil and tacrolimus were 44% and 41%, r

67 Mycophenolate mofetil and TNF-alpha antagonists can be u

68 All patients received tacrolimus and mycophenolate mofetil and underwent a 5-day glucocortico

69 ly oral methotrexate or 1 g twice daily oral mycophenolate mofetil and were monitored monthly for 6 m

70 inhibitor (CNI) dose or conversion to either mycophenolate mofetil and/or rapamycin resulted in varia

71 nance with tacrolimus/cyclosporine (FK/CSA), mycophenolate mofetil, and a rapid steroid taper.

72 plored for this disease including Rituximab, mycophenolate mofetil, and adrenocorticotropic hormone,

73 ion and maintenance therapy with tacrolimus, mycophenolate mofetil, and corticosteroids.

74 or induction in combination with tacrolimus, mycophenolate mofetil, and corticosteroids.

75 All subjects received basiliximab induction, mycophenolate mofetil, and corticosteroids.

76 RDP using thymoglobulin, mycophenolate mofetil, and CsA in selected pediatric KTx

77 sone tapered off over 6 days, thymoglobulin, mycophenolate mofetil, and cyclosporine A (CsA).

78 ter transplantation consisted of tacrolimus, mycophenolate mofetil, and glucocorticoids.

79 emotherapies cyclophosphamide, azathioprine, mycophenolate mofetil, and methotrexate.

80 t was evenly distributed among azathioprine, mycophenolate mofetil, and methotrexate.

81 ldren with SLE received cyclophosphamide and mycophenolate mofetil, and more children with JIA receiv

82 ppressive regime consisting of cyclosporine, mycophenolate mofetil, and prednisolone were well tolera

83 ept or tacrolimus combined with basiliximab, mycophenolate mofetil, and prednisolone.

84 te globulin, methylprednisolone, tacrolimus, mycophenolate mofetil, and prednisone were commenced.

85 Patients taking cyclosporine, mycophenolate mofetil, and prednisone were randomly assi

86 maintenance immunotherapy using tacrolimus, mycophenolate mofetil, and prednisone.

87 e immunosuppressive therapy with tacrolimus, mycophenolate mofetil, and prednisone.

88 d rabbit antithymocyte globulin, tacrolimus, mycophenolate mofetil, and prednisone.

89 e immunosuppression consisted of tacrolimus, mycophenolate mofetil, and rapidly tapered solumedrol wi

90 ntithymocyte globulin induction, tacrolimus, mycophenolate mofetil, and steroid withdrawal by day 5 a

91 40% (19%) and were maintained on tacrolimus, mycophenolate mofetil, and steroid.

92 ody induction followed by de novo sirolimus, mycophenolate mofetil, and steroids were compared; group

93 an induction antibody followed by sirolimus, mycophenolate mofetil, and steroids.

94 ion therapy, in combination with tacrolimus, mycophenolate mofetil, and steroids.

95 ndardized immunosuppression with tacrolimus, mycophenolate mofetil, and steroids.

96 tithymocyte globulin, calcineurin inhibitor, mycophenolate mofetil, and steroids.

97 ss costly than regimens consisting of a CNI, mycophenolate mofetil, and steroids; therefore, CNI with

98 ttransplantation high-dose cyclophosphamide, mycophenolate mofetil, and tacrolimus or sirolimus.

99 nance immunosuppression was with prednisone, mycophenolate mofetil, and tacrolimus.

100 tween the 2 groups consisting of prednisone, mycophenolate mofetil, and tacrolimus.

101 ing, T-cell-replete allografting, then PTCy, mycophenolate mofetil, and tacrolimus.

102 Both MPA and mycophenolate mofetil are highly specific inhibitors of

103 Calcineurin inhibitors and mycophenolate mofetil are potential salvage therapies, a

104 Tacrolimus and mycophenolate mofetil are promising therapies for proble

105 ting immunosuppression with cyclosporine and mycophenolate mofetil as a control group, we compared ou

106 ively affect patient survival and the use of mycophenolate mofetil as part of maintenance immunosuppr

107 Clinical trials evaluating mycophenolate mofetil as remission induction therapy, gu

108 Mycophenolate mofetil at intensified and individually ad

109 h enteric-coated mycophenolate sodium versus mycophenolate mofetil at month 6 among African Americans

110 deceased donor KTRs maintained on tacrolimus/mycophenolate mofetil-based regimen along with steroid.

111 eks, or tacrolimus QD 0.2 mg/kg per day with mycophenolate mofetil, basiliximab, and corticosteroids

112 lung disease, and the present preference for mycophenolate mofetil because of its better tolerability

113 Mycophenolate mofetil, budesonide, rapamycin, and 6-thio

114 ther reduced calcineurin inhibitor (CNI) and mycophenolate mofetil by 30% to 50% (n=23), or we switch

115 nation therapy with IFN-beta-1a (Avonex) and mycophenolate mofetil (Cellcept) modulated the hyperphos

116 lonal antibody induction with tacrolimus and mycophenolate mofetil combination maintenance, both regi

117 A total of 67 patients (35 methotrexate, 32 mycophenolate mofetil) contributed to the primary outcom

118 ee immunosuppressive regimen, when used with mycophenolate mofetil, corticosteroids, and anti-interle

119 her a CNI-free regimen, including sirolimus, mycophenolate mofetil, corticosteroids, and anti-interle

120 RL is most commonly used in combination with mycophenolate mofetil, CsA, or TAC.

121 eukin-2 receptor antibody for induction, and mycophenolate mofetil, cyclosporin A, and prednisone for

122 Postgrafting immunosuppression consisted of mycophenolate mofetil (days 0-27) in combination with 3

123 SRL+mycophenolate mofetil versus tacrolimus+mycophenolate mofetil de novo, and (d) conversion from C

124 ence proteinuria responses to cyclosporin or mycophenolate mofetil/dexamethasone.

125 Mycophenolate mofetil did not provide mycophenolic acid

126 Neither mycophenolate mofetil dose nor tacrolimus dose or trough

127 Mycophenolate mofetil dose reduction was independently a

128 300 and 225 to 275 ng/mL, respectively, and mycophenolate mofetil dose was adjusted according to 2 t

129 dose equal to or more than 2000 mg per day (mycophenolate mofetil equivalents) was significantly hig

130 ransplantation anemia (PTA) is common in the mycophenolate mofetil era, its impact on patient surviva

131 Tacrolimus or sirolimus and mycophenolate mofetil exposure was identical between gro

132 derma-related interstitial lung disease with mycophenolate mofetil for 2 years or cyclophosphamide fo

133 irradiation (200 cGy) with cyclosporine and mycophenolate mofetil for posttransplantation immunoprop

134 l effectiveness of both cyclophosphamide and mycophenolate mofetil for progressive scleroderma-relate

135 sitivity, hepatitis C virus reinfection, and mycophenolate mofetil-free regimens were significant ris

136 Relapses were more common in the mycophenolate mofetil group (42/76 patients) compared wi

137 ed from baseline to 24 months by 2.19 in the mycophenolate mofetil group (95% CI 0.53-3.84) and 2.88

138 e adverse events in 8 patients (7.5%) in the mycophenolate mofetil group (HR, 0.53 [95% CI, 0.23-1.18

139 thioprine group and in 23.5% of those in the mycophenolate mofetil group (P = 0.11), and the rate of

140 ilure were 16.4% (19 of 116 patients) in the mycophenolate mofetil group and 32.4% (36 of 111) in the

141 y kidney transplant recipients receiving 2 g mycophenolate mofetil (group A, n=75) versus 1.440 g ent

142 e hepatitis, and, in contrast to budesonide, mycophenolate mofetil has been effective in a small stud

143 Mycophenolate mofetil has emerged as a viable alternativ

144 Mycophenolate mofetil has not become the "wonder drug" t

145 % CI 0.61-0.90, P=0.003) and with the use of mycophenolate mofetil (HR=0.77, 95% CI 0.64-0.92, P=0.00

146 ptopurine (OR, 0.62; 95% CI, 0.15-2.53), and mycophenolate mofetil hydrochloride (OR, 0.66; 95% CI, 0

147 same conditioning regimen with sirolimus and mycophenolate mofetil immune suppression.

148 llowed by a short course of cyclosporine and mycophenolate mofetil immunosuppression.

149 olonged-release tacrolimus, basiliximab, and mycophenolate mofetil immunosuppressive regimen is effic

150 solimumab nonimprovers were downregulated in mycophenolate mofetil improvers, suggesting that immunom

151 We compared Everolimus versus mycophenolate mofetil in an investigator-initiated singl

152 provement was observed in patients receiving mycophenolate mofetil in any treatment combination (HR 0

153 are recent data demonstrating superiority of mycophenolate mofetil in certain subgroups.

154 he use of corticosteroids, azathioprine, and mycophenolate mofetil in ocular myasthenia gravis.

155 ted case reports of the use of rituximab and mycophenolate mofetil in resistant disease.

156 Mycophenolate mofetil is a potent immunosuppressant medi

157 l studies suggest that the immunosuppressant mycophenolate mofetil is associated with anemia.

158 hymocyte globulin induction, tacrolimus, and mycophenolate mofetil is associated with excellent patie

159 ith interstitial lung disease (ILD), whereas mycophenolate mofetil is effective in both polymyositis

160 tides (IMPROVE), to test the hypothesis that mycophenolate mofetil is more effective than azathioprin

161 Mycophenolate mofetil is, therefore, a suitable alternat

162 ntenance therapy, often with azathioprine or mycophenolate mofetil, is required to consolidate remiss

163 tagonist induction along with tacrolimus and mycophenolate mofetil maintenance.

164 Immunosuppression included mycophenolate mofetil (MMF) (2 g/day), tacrolimus (targe

165 or 3.0 mg with reduced-dose cyclosporine, or mycophenolate mofetil (MMF) 3 g/day with standard-dose c

166 -coated mycophenolate sodium (EC-MPS) versus mycophenolate mofetil (MMF) among renal transplant recip

167 Mycophenolate mofetil (MMF) and combination therapies in

168 Prophylactic drugs, such as mycophenolate mofetil (MMF) and cyclosporine A (CsA), ar

169 rns as to the safety of in utero exposure to mycophenolate mofetil (MMF) and sirolimus (SRL) in trans

170 acrolimus (TAC) or cyclosporine A (CsA) with mycophenolate mofetil (MMF) and steroids after heart tra

171 ceiving tacrolimus (Tac) in combination with mycophenolate mofetil (MMF) and those maintained on a re

172 -coated mycophenolate sodium (EC-MPS) versus mycophenolate mofetil (MMF) and to examine the impact of

173 Nowadays, tacrolimus (Tac) and mycophenolate mofetil (MMF) are considered more efficien

174 atical model using T- and B-cell markers and mycophenolate mofetil (MMF) dosage.

175 id corticosteroid withdrawal, tacrolimus and mycophenolate mofetil (MMF) for 1 month followed by rand

176 Clinicians are increasingly using mycophenolate mofetil (MMF) for the treatment of systemi

177 d with tacrolimus (Tac) and dose-intensified mycophenolate mofetil (MMF) further adjusted individuall

178 calcineurin inhibitor (CNI) withdrawal with mycophenolate mofetil (MMF) has not become routine pract

179 Rapamycin and mycophenolate mofetil (MMF) have been used for maintenan

180 r trial to determine whether the addition of mycophenolate mofetil (MMF) improves the efficacy of ini

181 e evidence of favorable long-term effects of mycophenolate mofetil (MMF) in renal transplantation, it

182 well as to characterize dose adjustments of mycophenolate mofetil (MMF) in this setting.

183 ebo-controlled study of daclizumab (DZB) and mycophenolate mofetil (MMF) including DZB(+)MMF(+), DZB(

184 nzyme activity and adverse effects caused by mycophenolate mofetil (MMF) inhibition may be geneticall

185 Mycophenolate mofetil (MMF) is an alternative to cycloph

186 The use of mycophenolate mofetil (MMF) is associated with less acut

187 The prodrug ester mycophenolate mofetil (MMF) is frequently used in solid-

188 -coated mycophenolate sodium (EC-MPS) versus mycophenolate mofetil (MMF) maintenance immunosuppressio

189 Recent studies have suggested that mycophenolate mofetil (MMF) may offer advantages over in

190 ssigned 1:1 on day 28 posttransplantation to mycophenolate mofetil (MMF) or Everolimus combined with

191 -blinded trial, was designed to test whether mycophenolate mofetil (MMF) plus corticosteroids was sup

192 Mycophenolate mofetil (MMF) provides superior prophylaxi

193 Mycophenolate mofetil (MMF) side effects often prompt do

194 st basiliximab induction with tacrolimus and mycophenolate mofetil (MMF) therapy in renal transplanta

195 el studies demonstrated that conversion from mycophenolate mofetil (MMF) to enteric-coated mycophenol

196 The benefit of conversion from mycophenolate mofetil (MMF) to enteric-coated mycophenol

197 Rodnan skin score (MRSS) improvement during mycophenolate mofetil (MMF) treatment.

198 Mycophenolate mofetil (MMF) use in renal transplantation

199 Mycophenolate mofetil (MMF) use may be associated with p

200 orine (n=30) after basiliximab induction and mycophenolate mofetil (MMF) with steroids.

201 udy was to assess the effects of late CNI or mycophenolate mofetil (MMF) withdrawal on ambulatory blo

202 We examined the effects of late CNI or mycophenolate mofetil (MMF) withdrawal on echocardiograp

203 teroids during 1999-2001 and then tacrolimus+mycophenolate mofetil (MMF)+daclizumab (steroid-free) vs

204 Mycophenolate mofetil (MMF), a prodrug of mycophenolic a

205 Mycophenolate Mofetil (MMF), a prodrug of mycophenolic a

206 rd maintenance dosing with tacrolimus (TAC), mycophenolate mofetil (MMF), and corticosteroids.

207 to compare tacrolimus/sirolimus, tacrolimus/mycophenolate mofetil (MMF), and cyclosporine/sirolimus.

208 xamined the association of tacrolimus (TAC), mycophenolate mofetil (MMF), and prednisone with BKN in

209 with tacrolimus (FK) or cyclosporine (CSA), mycophenolate mofetil (MMF), and steroids versus no calc

210 icularly with the combination of tacrolimus, mycophenolate mofetil (MMF), and steroids.

211 All patients were initially treated with mycophenolate mofetil (MMF), cyclosporine A (CsA), and p

212 rolled trial comparing early CW (tacrolimus, mycophenolate mofetil (MMF), daclizumab, and corticoster

213 rednisolone 2 mg/kg per day plus etanercept, mycophenolate mofetil (MMF), denileukin diftitox (denile

214 nistration of a 3-drug regimen consisting of mycophenolate mofetil (MMF), sirolimus, and the anti-IL-

215 sporine A (CSA), but not rapamycin (RAPA) or mycophenolate mofetil (MMF), suppressed Treg function as

216 eated with the combination of tacrolimus and mycophenolate mofetil (MMF).

217 event rates for EC-MPS were comparable with mycophenolate mofetil (MMF).

218 dnisone-free maintenance with tacrolimus and mycophenolate mofetil (MMF).

219 itor (CNI) with either methotrexate (MTX) or mycophenolate mofetil (MMF).

220 ines were treated with the immunosuppressant mycophenolate mofetil (MMF).

221 ng maintenance with both corticosteroids and mycophenolate mofetil (MMF).

222 drug and a calcineurin inhibitor as follows: mycophenolate mofetil (MMF)/mycophenolate sodium+tacroli

223 eived tacrolimus (FK-506, 0.1 mg/kg per day)/mycophenolate mofetil (MMF, 60 mg/kg per day), and anti-

224 ation of the drug was a prodrug formulation, mycophenolate mofetil (MMF, Cellcept), which is well abs

225 Immunosuppression included mycophenolate mofetil (MMF, n=16) and sirolimus (n=16).

226 ip), tacrolimus (FK506; 0.1-0.5-1 mg/kg ip), mycophenolate mofetil (MMF; 60-120-300 mg/kg oral) or ve

227 ficacy and safety of a 1-year treatment with mycophenolate mofetil (MMF; target plasma mycophenolic a

228 Prednisolone, tacrolimus, and mycophenolate mofetil modified fecal microbiota at the f

229 ts were assigned to azathioprine (n = 80) or mycophenolate mofetil (n = 76) and were followed up for

230 42 patients were randomly assigned to either mycophenolate mofetil (n=69) or cyclophosphamide (n=73).

231 126 patients (mycophenolate mofetil [n=63] and cyclophosphamide [n=63]

232 s), with an unadjusted hazard ratio (HR) for mycophenolate mofetil of 1.69 (95% confidence interval [

233 The effect of sirolimus or mycophenolate mofetil on NK cells was minimal.

234 henolic acid (MPA), the active metabolite of mycophenolate mofetil, on erythropoiesis in vitro.

235 Maintenance therapy included mycophenolate mofetil or azathioprine plus glucocorticoi

236 nts received systemic immunosuppression with mycophenolate mofetil or cyclosporine A.

237 had worsened gastrointestinal symptoms with mycophenolate mofetil or EC-MPS in combination with Tac

238 were normalized after treatment with either mycophenolate mofetil or intravenous cyclophosphamide.

239 The maintenance regimen of tacrolimus and mycophenolate mofetil or mycophenolate sodium was associ

240 =0.003) than the regimen of cyclosporine and mycophenolate mofetil or mycophenolate sodium.

241 Whether treatments such as mycophenolate mofetil or statins have a role in preventi

242 RTRs who were male, nonwhite, or used mycophenolate mofetil or tacrolimus were more likely to

243 tment success with methotrexate and 47% with mycophenolate mofetil (P = 0.09).

244 ), and higher mean tacrolimus (P=0.0009) and mycophenolate mofetil (P=0.01) blood levels.

245 antithymocyte globulin induction followed by mycophenolate mofetil plus calcineurin inhibitors (n=28,

246 uded maintenance therapy with belatacept and mycophenolate mofetil plus induction with basiliximab an

247 adults who were randomized to cyclosporin or mycophenolate mofetil plus pulse oral dexamethasone with

248 unosuppressive protocol included tacrolimus, mycophenolate mofetil, prednisone, and antithymocyte glo

249 pressive treatment that included tacrolimus, mycophenolate mofetil, prednisone, and, for induction, a

250 uccess in transitioning to azathioprine from mycophenolate mofetil prior to pregnancy in patients wit

251 l randomized controlled trial, International Mycophenolate Mofetil Protocol to Reduce Outbreaks of Va

252 The Tricontinental Mycophenolate Mofetil Renal Transplantation Study was a

253 temic sclerosis treated with five therapies: mycophenolate mofetil, rituximab, abatacept, nilotinib,

254 Monitored drugs were mycophenolate mofetil, sirolimus, or azathioprine.

255 ent three-drug combinations of cyclosporine, mycophenolate mofetil, sirolimus, or methotrexate after

256 , tacrolimus (FK), cyclosporine A (CSA), and mycophenolate mofetil/sodium (MMF).

257 d to azathioprine (starting at 2 mg/kg/d) or mycophenolate mofetil (starting at 2000 mg/d) after indu

258 d were discharged on a calcineurin inhibitor/mycophenolate mofetil/steroid-free immunosuppression.

259 cipients maintained on calcineurin inhibitor/mycophenolate mofetil/steroid-free regimen.

260 olimus/basiliximab [Tac/Bas], 139 tacrolimus/mycophenolate mofetil [Tac/MMF], and 139 tacrolimus/MMF/

261 were treated for 14 days with prednisolone, mycophenolate mofetil, tacrolimus, a combination of thes

262 l islet grafts under anti-thymocyte globulin-mycophenolate mofetil-tacrolimus protocol.

263 oglobulin/interleukin 2 receptor blocker and mycophenolate mofetil/tacrolimus (Tac)/prednisone was em

264 ted for the study (n = 370) and treated with mycophenolate mofetil (target dosage 3 gm/day) or intrav

265 mmy, centre-blocked design to receive either mycophenolate mofetil (target dose 1500 mg twice daily)

266 Fewer patients on mycophenolate mofetil than on cyclophosphamide premature

267 Combined prednisone and mycophenolate mofetil therapy is a potentially effective

268 Switching from mycophenolate mofetil to leflunomide successfully cleare

269 molluscum contagiosum who were switched from mycophenolate mofetil to leflunomide.

270 It compared the addition of mycophenolate mofetil to steroids vs steroids/placebo to

271 e 5'-monophosphate dehydrogenase inhibitors (mycophenolate mofetil) to the immunosuppressive armament

272 for 2 weeks after each infusion); rapamycin+mycophenolate mofetil treatment as maintenance therapy.

273 Immunosuppressant mycophenolate mofetil treatment of enriched IL-17A(+) ce

274 either 25 mg oral methotrexate weekly or 1 g mycophenolate mofetil twice daily, with a corticosteroid

275 Finally, delaying cyclosporine and mycophenolate mofetil until after MTX administration did

276 IS consisted of ATG, anti-CD154mAb, and mycophenolate mofetil until age 8 to 12 months.

277 while low DNAemia rates were associated with mycophenolate mofetil use (p < 0.0001) and EBV viral cap

278 acrolimus elimination at 3 months versus SRL+mycophenolate mofetil versus tacrolimus+mycophenolate mo

279 Mycophenolate mofetil was associated with PCP risk only

280 Although mycophenolate mofetil was better tolerated and associate

281 Mycophenolate mofetil was initiated postoperatively with

282 Use of mycophenolate mofetil was inversely associated with vacc

283 Among patients with AAV, mycophenolate mofetil was less effective than azathiopri

284 , the addition of a calcineurin inhibitor or mycophenolate mofetil was predictive for maintaining a D

285 Mycophenolate mofetil was superior to azathioprine in ma

286 Mycophenolate mofetil was superior to azathioprine with

287 Mycophenolate mofetil was the treatment in 10 patients,

288 hen given in combination with tacrolimus and mycophenolate mofetil, was first demonstrated after nonm

289 Thymoglobulin induction, tacrolimus, and mycophenolate mofetil were also associated.

290 r pretransplant IgG level and treatment with mycophenolate mofetil were associated with lower IgG lev

291 iral prophylaxis, CMV serostatus, and use of mycophenolate mofetil were each associated with risk of

292 Tacrolimus and mycophenolate mofetil were required as well as either ra

293 ab 1 month before transplant; tacrolimus and mycophenolate mofetil were started 1 week before surgery

294 nosuppressive protocol with cyclosporine and mycophenolate mofetil were used for comparison.

295 A calcineurin inhibitor and mycophenolate mofetil were used for postgrafting immunos

296 ession with oral tacrolimus, prednisone, and mycophenolate mofetil, which has continued until the pre

297 ic approaches, such as biological agents and mycophenolate mofetil, will also be discussed.

298 enance immunosuppression with tacrolimus and mycophenolate mofetil with/without steroids.

299 mmunosuppression consisted of tacrolimus and mycophenolate mofetil without induction or depletional t

300 We hypothesised that a 2 year course of mycophenolate mofetil would be safer, better tolerated,